Latest filing published 21 Sept 2022 for Adverum Biotechnologies, Inc., €4,556.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Richard Beckman: trading record in brief
Richard Beckman is a declared insider of Adverum Biotechnologies, Inc. (senior executive), with filings sourced from SEC (Form 4). Over a trading history stretching from 17 May 2022 to 19 September 2022, the count stands at 4 filings.
In open-market terms, that means 1 purchase worth €7,801 on one side and 1 sale worth €4,556 on the other. Netting one side against the other leaves €3,244 of net buying. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 2 share grants.
On 21 September 2022 came the latest disclosure, an open-market sale for €4,556 in Adverum Biotechnologies, Inc. The last insider purchase was made public on 19 May 2022, 1,636 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Richard Beckman
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 4,272 shares@ US$1.069736.9% of flowCommon StockSEC:0001209191-22-050957:0
- 33,333 shares0Common StockSEC:0001209191-22-050950:0
- 25,000 shares0Common StockSEC:0001209191-22-050417:0
- 10,000 shares@ US$0.822863.1% of flowCommon StockSEC:0001209191-22-030774:0Canonical exit: 15 Aug 2022 (T+90)
4 of 4 declarations